Empower Clinics Inc (CSE:CBDT) (OTCQB:EPWCF) (FRA:8EC) announced Monday that its KAI Medical Laboratory in Dallas, Texas has exceeded 1,000 coronavirus (COVID-19) test units in a single day for the first time.
As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the US, Canada, and international markets.
The company acquired the state-of-the-art diagnostics laboratory last October to further advance the company's COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses, and the travel industry.
Empower said the lab experienced significant growth in its first-quarter under the company (October 2020 to December 2020), with COVID-19 test units exceeding 6,000 specimens processed, far surpassing the less than 1,000 total monthly units prior to acquisition.
As a result, Empower last month announced that it would be double testing volumes -- but is now revising again this planned expansion upwards by tripling its current size in anticipation of projected growth in COVID-19 test requirements.
"Today marks a significant milestone for Empower and our shareholders,” said Empower CEO Steven McAuley in a statement.
“When we first acquired KAI Medical Laboratory just over four months ago, it was processing less than 1,000 specimens monthly up to that point. Today, we are announcing that KAI has surpassed 1,000 units in a day for the first time ever. This is a credit to both Yoshi Tyler, President KAI LAB and her fantastic team, supported by our business development and marketing strategies which, quite frankly, are still in an early phase. We are just getting started."
For the purposes of facilitating the expansion, Empower said it has secured additional space adjacent to KAI LAB to separate the lab & science from logistics, administration, and customer support. Materials-handling staff are being added in anticipation of processing the intake of thousands of packages per day.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham